EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience

Marina Romozzi, Adolfo Mazzeo, Matteo Antonucci, Giovanni Assenza, Maria Antonietta Bassetti, Mariana Fernandes, Claudio Liguori iD, Giulia Lippa, Marta Piccioli, Patrizia Pulitano, Paolo Tisei, Mario Tombini und 3 weitere

Epilepsia Open · 16.11.2026

DOI: 10.1002/epi4.70365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, online erschienen am 16.11.2026. Verfasst von Marina Romozzi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cenobamate (CNB) is a novel antiseizure medication with a dual mechanism of action that has demonstrated high efficacy in drug‐resistant focal epilepsy; however, evidence in brain tumor‐related epilepsy (BTRE) remains limited. The study aimed to evaluate the effectiveness, safety, and tolerability of CNB as add‐on therapy in a multicenter cohort of patients with BTRE.

Methods

We conducted a multicenter, retrospective observational study across tertiary epilepsy centers in the Lazio region, Italy. Adult patients with drug‐resistant BTRE treated with CNB as adjunctive therapy were included. Seizure frequency was assessed at baseline and during follow‐up. Primary outcomes were changes in monthly seizure frequency and responder rates. Effectiveness was analyzed in both the overall population and in a homogeneous cohort of patients with 6‐month follow‐up.

Results

Twenty patients (10 females, median age 48 years) were included. Tumor histology included meningioma ( n = 7, 35%), astrocytoma ( n = 4, 20%), glioblastoma ( n = 3, 15%), ganglioglioma ( n = 3, 15%), oligodendroglioma ( n = 2, 10%), and dysembryoplastic neuroepithelial tumor ( n = 1, 5%). In the overall analysis population ( n = 20), after a median 12‐month follow‐up, median seizure frequency significantly decreased from 6 to 1 per month (p < 0.001), with a median reduction of 85.8% (IQR 51.4–96.7). Responder rates were 80% (≥50% seizure reduction), 60% (≥75%), and 20% achieved seizure freedom. Adverse events occurred in 12 patients (60%), including sedation ( n = 8, 40%), postural instability ( n = 3, 15%), diarrhea, and mild cutaneous rash ( n = 1, 5% each). CNB was discontinued in one patient (5%). Significance In this multicenter real‐world cohort of patients with drug‐resistant BTRE and heterogeneous tumor histology, CNB was associated with a reduction in seizure frequency and was well tolerated. Plain Language Summary Seizures caused by brain tumors can be difficult to control. We reviewed records from 20 adults who received cenobamate alongside their existing seizure medicines. At their last follow‐up, 16 had at least half as many seizures, and four were seizure‐free. Twelve patients experienced side effects, most commonly sleepiness; one stopped cenobamate because of a rash. These findings suggest that cenobamate may help some people with brain tumor‐related epilepsy. However, the study was small, had no comparison group, and included patients with different tumors and follow‐up durations. Larger studies are needed.

Schlagwörter

Stichwörter der Autor:innen

BTREantiseizure medicationsglioblastoma

Autor:innen und Institutionen

  • Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Neurology Unit, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Human Neurosciences, 'Sapienza' University of Rome, Rome, Italy.
  • Epilepsy Centre, Neurology Unit, University Hospital of Tor Vergata, Rome, Italy.
  • Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • UOC Neurologia, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.

ORCID-Profile: Claudio Liguori

Zitieren

APA

Romozzi, M., Mazzeo, A., Antonucci, M., Assenza, G., Bassetti, M. A., Fernandes, M., Liguori, C., Lippa, G., Piccioli, M., Pulitano, P., Tisei, P., Tombini, M., Calabresi, P., Vollono, C., & Maschio, M. (2026). Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience. Epilepsia Open. https://doi.org/10.1002/epi4.70365

Vancouver

Romozzi M, Mazzeo A, Antonucci M, Assenza G, Bassetti MA, Fernandes M, et al. Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience. Epilepsia Open. 2026. doi:10.1002/epi4.70365

BibTeX
@article{Romozzi2026,
  author = {Romozzi, Marina and Mazzeo, Adolfo and Antonucci, Matteo and Assenza, Giovanni and Bassetti, Maria Antonietta and Fernandes, Mariana and Liguori, Claudio and Lippa, Giulia and Piccioli, Marta and Pulitano, Patrizia and Tisei, Paolo and Tombini, Mario and Calabresi, Paolo and Vollono, Catello and Maschio, Marta},
  title = {Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience},
  journal = {Epilepsia Open},
  year = {2026},
  doi = {10.1002/epi4.70365}
}
Kostenlos starten →